[go: up one dir, main page]

WO2008129270A3 - Compositions comprising anti-inflammatory compounds - Google Patents

Compositions comprising anti-inflammatory compounds Download PDF

Info

Publication number
WO2008129270A3
WO2008129270A3 PCT/GB2008/001373 GB2008001373W WO2008129270A3 WO 2008129270 A3 WO2008129270 A3 WO 2008129270A3 GB 2008001373 W GB2008001373 W GB 2008001373W WO 2008129270 A3 WO2008129270 A3 WO 2008129270A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
nsaid
compositions
composition
inflammatory compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/001373
Other languages
French (fr)
Other versions
WO2008129270A2 (en
Inventor
Robert Damms
Humphery-Smith Ian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOSYSTEMS INFORMATICS INSTITUTE
BIOSYSTEMS INFORMATICS INST
RENAISSANCE PHARMA Ltd
Original Assignee
BIOSYSTEMS INFORMATICS INSTITUTE
BIOSYSTEMS INFORMATICS INST
RENAISSANCE PHARMA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOSYSTEMS INFORMATICS INSTITUTE, BIOSYSTEMS INFORMATICS INST, RENAISSANCE PHARMA Ltd filed Critical BIOSYSTEMS INFORMATICS INSTITUTE
Publication of WO2008129270A2 publication Critical patent/WO2008129270A2/en
Publication of WO2008129270A3 publication Critical patent/WO2008129270A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides compositions for providing an effective therapeutic effect at lower drug dosages. A composition of the invention comprises a first formulation of a non-steroidal anti-inflammatory compound (NSAID) and a second formulation of the same NSAID, wherein the dosage amount of the NSAID in the first formulation is higher than that of the second formulation, and wherein the second formulation is a pulsed release formulation which, on administration of the composition, releases the NSAID at a time interval of greater than 12 minutes after the release of the NSAID of the first formulation.
PCT/GB2008/001373 2007-04-18 2008-04-18 Compositions comprising anti-inflammatory compounds Ceased WO2008129270A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0707489.1 2007-04-18
GBGB0707489.1A GB0707489D0 (en) 2007-04-18 2007-04-18 Compounds

Publications (2)

Publication Number Publication Date
WO2008129270A2 WO2008129270A2 (en) 2008-10-30
WO2008129270A3 true WO2008129270A3 (en) 2008-12-18

Family

ID=38116947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/001373 Ceased WO2008129270A2 (en) 2007-04-18 2008-04-18 Compositions comprising anti-inflammatory compounds

Country Status (2)

Country Link
GB (1) GB0707489D0 (en)
WO (1) WO2008129270A2 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1276089A (en) * 1968-08-23 1972-06-01 Pfizer Ltd Pharmaceutical preparations
US4025613A (en) * 1971-07-19 1977-05-24 Richard G. Powers Timed-release aspirin
EP0105065A1 (en) * 1982-10-05 1984-04-11 Kishan Narain Mathur A pharmaceutical composition for pain relief
EP0239361A1 (en) * 1986-03-27 1987-09-30 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
EP0411590A2 (en) * 1989-08-02 1991-02-06 ARNOLD, John David Method and preparation for reducing risk of myocardial infarction
GB2306109A (en) * 1997-02-07 1997-04-30 John Wright A zinc containing composition for treating the common cold
WO2001037813A2 (en) * 1999-11-24 2001-05-31 Lts Lohmann Therapie-Systeme Ag Multilayer preparation for a controlled, pulsed release of active substances
WO2006049978A1 (en) * 2004-10-28 2006-05-11 Novartis Ag Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent fr enhanced absorption

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1276089A (en) * 1968-08-23 1972-06-01 Pfizer Ltd Pharmaceutical preparations
US4025613A (en) * 1971-07-19 1977-05-24 Richard G. Powers Timed-release aspirin
EP0105065A1 (en) * 1982-10-05 1984-04-11 Kishan Narain Mathur A pharmaceutical composition for pain relief
EP0239361A1 (en) * 1986-03-27 1987-09-30 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
EP0411590A2 (en) * 1989-08-02 1991-02-06 ARNOLD, John David Method and preparation for reducing risk of myocardial infarction
GB2306109A (en) * 1997-02-07 1997-04-30 John Wright A zinc containing composition for treating the common cold
WO2001037813A2 (en) * 1999-11-24 2001-05-31 Lts Lohmann Therapie-Systeme Ag Multilayer preparation for a controlled, pulsed release of active substances
WO2006049978A1 (en) * 2004-10-28 2006-05-11 Novartis Ag Composition comprising acetaminophen, caffeine and optionally aspirin together with an alkiline agent fr enhanced absorption

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CATELLA-LAWSON F ET AL: "CYCLOOXYGENASE INHIBITORS AND THE ANTIPLATELET EFFECTS OF ASPIRIN", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 345, no. 25, 20 December 2001 (2001-12-20), pages 1809 - 1817, XP001118002, ISSN: 0028-4793 *

Also Published As

Publication number Publication date
GB0707489D0 (en) 2007-05-23
WO2008129270A2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
AU2007247480A8 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and an NSAID
WO2007112274A3 (en) Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
BRPI0516718A (en) modified release ibuprofen dosage form
WO2006056711A3 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
WO2007126832A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
WO2005032474A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
UA94942C2 (en) Dpp iv inhibitor formulations
CL2008000750A1 (en) METHOD FOR THE ADMINISTRATION OF A WEEKLY DOSE OF 2- [6- (3-AMINO-PIPERIDIN-1-IL) 3-METHYL-2,4 DIOXO-3,4 DIHYDRO-2H-PIRIMIDIN-1-IL METIL] -4 FLUORO-BENZONITRILE; PHARMACEUTICAL COMPOSITION OF AN INDIVIDUAL DOSAGE FORM OF SUCH COMPOUND; AND HIS
TW200517106A (en) Sustained release pharmaceutical compositions
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2007127725A3 (en) Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods
CY1111369T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 3- (3-DIMETHYLAMINE-1-ETHYL-2-Methyl-PROPYL) -PHENOL AND PARAKETAMOL
PE20150773A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
BRPI0412364A (en) solid pharmaceutical composition comprising amisulpride
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
MXPA02010828A (en) Pharmaceutical composition in capsules comprising a non-steroidal anti-inflammatory and an opiate analgesic for handling pain.
WO2008129270A3 (en) Compositions comprising anti-inflammatory compounds
WO2003061572A3 (en) Anti-inflammatory formulations
JO3239B1 (en) Galenical Formulations of Organic Compounds
WO2007011958A3 (en) Intraoral dosage forms of glucagon
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08737032

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08737032

Country of ref document: EP

Kind code of ref document: A2